Title
Reversal of visceral hypersensitivity in rat by Menthacarin®, a proprietary combination of essential oils from peppermint and caraway, coincides with mycobiome modulation
Author
Botschuijver, S.
Welting, O.
Levin, E.
Maria-Ferreira, D.
Koch, E.
Montijn, R.C.
Seppen, J.
Hakvoort, T.B.M.
Schuren, F.H.J.
de Jonge, W.J.
van den Wijngaard, R.M.
Publication year
2018
Abstract
Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder associated with altered gastrointestinal microflora and increased nociception to colonic distension. This visceral hypersensitivity can be reversed in our rat maternal separation model by fungicides. Menthacarin® is a proprietary combination of essential oils from Mentha x piperita L. and Carum carvi. Because these oils exhibit antifungal and antibacterial properties, we investigated whether Menthacarin® can reverse existing visceral hypersensitivity in maternally separated rats. Methods: In non-handled and maternally separated rats, we used the visceromotor responses to colorectal distension as measure for visceral sensitivity. We evaluated this response before and 24 hours after water-avoidance stress and after 7 days treatment with Menthacarin® or control. The pre- and post-treatment mycobiome and microbiome were characterized by sequencing of fungal internal transcribed spacer 1 (ITS-1) and bacterial 16s rDNA regions. In vitro antifungal and antimicrobial properties of Menthacarin® were studied with radial diffusion assay. Key Results: Menthacarin® inhibited in vitro growth of yeast and bacteria. Water-avoidance caused visceral hypersensitivity in maternally separated rats, and this was reversed by treatment. Multivariate analyses of ITS-1 and 16S high throughput data showed that maternal separation, induced changes in the myco- and microbiome. Menthacarin® treatment of non-handled and maternally separated rats shifted the mycobiomes to more similar compositions. Conclusions & Inferences: The development of visceral hypersensitivity in maternally separated rats and the Menthacarin®-mediated reversal of hypersensitivity is associated with changes in the mycobiome. Therefore, Menthacarin® may be a safe and effective treatment option that should be tested for IBS. © 2018 The Authors. Neurogastroenterology & Motility Published by John Wiley & Sons Ltd. Chemicals / CAS: decanoic acid, 334-48-5, 3398-75-2; fluconazole, 86386-73-4; octanoic acid, 124-07-2, 1984-06-1, 74-81-7; peppermint oil, 8006-90-4; streptomycin, 57-92-1
Subject
Abdominal pain
Bacteria
Fungi
IBS
Microbiome
Antibiotic agent
Antifungal agent
Bacterial DNA
Caraway oil
Decanoic acid
Digestive tract agent
DNA 16S
DNA 18S
Essential oil
Fluconazole
Fungal DNA
Internal transcribed spacer 1
Menthacarin
Octanoic acid
Penicillin derivative
Peppermint oil
Streptomycin
Unclassified drug
Animal experiment
Animal model
Antibacterial activity
Antifungal activity
Assay
Bacillus subtilis
Candida albicans
Caraway
Colorectal disease
Colorectal distension
Controlled study
Digestive function
Digestive system disease
Dose response
Drug dose comparison
Drug efficacy
Drug mechanism
Drug megadose
Dysbiosis
Female
Growth inhibition
High throughput sequencing
Hypersensitivity
In vitro study
Intestine flora
Low drug dose
Male
Maternal deprivation
Mentha piperita
Motor activity
Mycobiome
Nonhuman
Physical sensitivity
Priority journal
Radial diffusion assay
Rat
Species composition
Treatment response
Viscera
Visceral hypersensitivity
Visceral hypersensitivity
Visceral sensitivity
To reference this document use:
http://resolver.tudelft.nl/uuid:9266bbb1-c00f-420f-b6e5-8ba141776eb4
DOI
https://doi.org/10.1111/nmo.13299
TNO identifier
810154
ISSN
1350-1925
Source
Neurogastroenterology and Motility, 30 (30)
Document type
article